

DAFTAR PUSTAKA

- Abbasi Asl M BF, Gohari M, Roudbary M, Khodabakhshi R. *Survival analysis of colorectal cancer patients and its prognostic factors using cox regression. Razi J Med Sci.* 2015;22:21–8.
- American Institute for Cancer Research. *Diet, Nutrition, Physical Activity and Colorectal Cancer.* American Institute for Cancer Research. 2018.
- Arnold M, Sierra MS, Laversanne M, et al. *Global patterns and trends in colorectal cancer incidence and mortality. Gut.* 2017;66:683–91
- Augestad, KM, Norum J, Dehof S, et al. *Cost-Effectiveness and Quality of Life in Surgeon Versus General Practitioner-Organised Colon Cancer Surveillance: A Randomised Controlled Trial. BMJ Open.* 2013, 3.
- Belderbos, Tim D.G. et al. *Long-Term Recurrence-Free Survival After Standard Endoscopic Resection Versus Surgical Resection Of Submucosal Invasive Colorectal Cancer: A Population-Based Study. Clinical Gastroenterology and Hepatology* 2017;15:403–411
- Béнар, Florence, et al. *Systematic Review of Colorectal Cancer Screening Guidelines for Average-Risk Adults: Summarizing The Current Global Recommendations. World J Gastroenterol.* 2018.
- Bosetti C, Bertuccio P, Malvezzi M et al. *Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol.* 2013.

- Bray F, Ferlay J, Soerjomataram I, *et al.* *Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.* *CA Cancer J Clin.* 2018, 68. Pp :394–424.
- Brouwer, Nelleke P.M. Brouwer, Amanda C.R.K. Bos, Valery E.P.P. Lemmens, *et al.* *An Overview of 25 Years of Incidence, Treatment and Outcome of Colorectal Cancer Patients.* *Int. J. Cancer.* 2018; 143: pp. 2758–2766. De Lau W , Peng WC , Gros P *et al.* *The R-spondin/LGR5/RNF43 Module: Regulator of Wnt Signal Strength.* ***Genes Dev.*** 2014, 28 (4). Pp: 305–316.
- Bullard KM, Rothenberger DA. 2010. *Colon, Rectum, and Anus. Schwartz's Principles of Surgery, 9th Edition.* New York: McGraw-Hill Medical Publishing Division.. p.1365-1382.
- Chen, Qing, Xin Zhang, Wei-Min Li. *Prognostic Value of LGR5 in Colorectal Cancer: A MetaAnalysis.* *PLoS ONE.* 2014; 9(9): e107013. DOI:10.1371/journal.pone.0107013.
- De Sousa E Melo, F. *et al.* (2017) 'A distinct role for Lgr5 + stem cells in primary and metastatic colon cancer', *Nature*, 543(7647), pp. 676–680. doi: 10.1038/nature21713.
- Devon KM, Vergara-Fernandez O, Victor JC and McLeod RS. *Colorectal cancer surgery in elderly patients: presentation, treatment, and outcomes.* *Dis Colon Rectum.* 2009; 52(7): 1272-1277.

- Dharmayanti, Sri, *et al.* *Imunoekspresi Lgr5 dan E-cadherin sebagai Faktor Prediksi Metastasis ke Kelenjar Getah Bening Regional pada Adenokarsinoma Kolorektal.* 2019.
- Elsafi, Salah H. *et al.* *The Sensitivity, Specificity, Predictive Values, and Likelihood Ratios of Fecal Occult Blood Test for The Detection of Colorectal Cancer in Hospital Settings. Clinical and Experimental Gastroenterology.* 2015.
- Espersen, Maiken Lise Marcker, Jesper Olsen, Dorte Linnemann, *et al.* *Clinical Implications of Intestinal Stem Cell Markers in Colorectal Cancer. Clinical Colorectal Cancer.* 2015; 14(2) : pp. 63-71.
- Fatemi, Seyed Reza *et al.* *Recurrence And Five Year Survival In Colorectal Cancer Patients After Surgery. Iranian Journal Of Cancer Prevention.* 2015; 8(4). Kowsar Medical Institute, DOI:10.17795/ijcp.3439. Accessed 22 May 2020.
- Fleming M, Ravula S, Tatishchev SF, Wang HL. *Colorectal carcinoma: Pathologic aspects. J Gastrointest Oncol.* 2012;3(3):153-173. DOI: 10.3978/j.issn.2078-6891.2012.030.
- Fujii, M. and Sato, T. (2017) 'Defining the role of Lgr5+ stem cells in colorectal cancer: From basic research to clinical applications', *Genome Medicine*, 9(1), pp. 1–4. doi: 10.1186/s13073-017-0460-y.
- GLOBOCAN. 2018. *Cancer today. International Agency for Research on Cancer.* <http://gco.iarc.fr/>

Gzil, A. et al. (2020) 'The prognostic value of leucine-rich repeat-containing G-protein (Lgr5) and its impact on clinicopathological features of colorectal cancer', *Journal of Cancer Research and Clinical Oncology*, 146(10), pp. 2547–2557. doi: 10.1007/s00432-020-03314-7.

Hassan, Muhammad Radzi Abu, Mohd Azri Mohd Suan, Shahrul Aiman Soelar, et al. *Survival Analysis and Prognostic Factors for Colorectal Cancer Patients in Malaysia. Asian Pac J Cancer Prev.* 2016; 17 (7), 3575-3581. DOI : 10.14456/apjcp.2016.136/APJCP.2016.17.7.3575.

Hamilton SR, Bosman FT, Boffetta P, et al. *Carcinoma of the colon and rectum. In: WHO Classification of Tumours of the Digestive System. Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. Lyon: IARC Press.* 2010:134-46.

Hanifah A.M., Ismet M.N., Fajar A.Y. *Gambaran Karakteristik Penderita Kanker Kolorektal di Bagian Patologi Anatomi Rumah Sakit Al-Islam Bandung Periode 2012- Prosiding Pendidikan Dokter.* 2016.. 3(2):61-71.

Harb, Ola A, et al. *Prognostic Value of Immunohistochemical Expressions of the Stem Cell Biomarker "LGR5" and the Proliferation Biomarker "TPX2" in Colorectal Carcinoma. ACT.* 2016.

Hong YJ, Han HS, Jeong Y, et al. *Impact of hyperglycemia on survival and infection-related adverse events in patients with metastatic colorectal*

cancer who were receiving palliative chemotherapy. Cancer Res Treatment. 2014; 46, 288-96.

Hsu T-W, Wei C-K, Yin W-Y, et al. *Prognostic Factors Affecting Short-Term Outcome of Curative Rectal Cancer Resection. Tzu Chi Med J.* 2013, 25(1). Pp :47–50.

IARC Working Group. *Evaluation of Cancer-Preventive Interventions. Colorectal cancer screening. Lyon (FR): International Agency for Research on Cancer.* 2019, 1. COLORECTAL CANCER.

Ihemelandu, Chukwuemeka et al. *Clinicopathologic and prognostic significance of LGR5, a cancer stem cell marker in patients with colorectal cancer. Colorectal cancer.* 2019; 8(4) CRC11. 12 Nov. 2019, DOI:10.2217/crc-2019-0009.

Jang, Bo Gun, Hye Sung Kim, Weon Young Chang, et al. *Expression Profile of LGR5 and Its Prognostic Significance in Colorectal Cancer Progression. Am J Pathol.* 2018; 188: 2236e2250. DOI : [https://doi.org/ 10.1016/j.ajpath.2018.06.012](https://doi.org/10.1016/j.ajpath.2018.06.012)

Jang, B. G., Kim, H. S., Chang, W. Y., Bae, J. M., Kim, W. H., & Kang, G. H. Expression Profile of LGR5 and Its Prognostic Significance in Colorectal Cancer Progression. *The American Journal of Pathology.* 2018. DOI:10.1016/j.ajpath.2018.06.012.

- Jiang, Y. *et al.* (2015) '*Lgr5 expression is a valuable prognostic factor for colorectal cancer: Evidence from a meta-analysis*', *BMC Cancer*, 15(1), pp. 1–10. doi: 10.1186/s12885-015-1985-3.
- Joachim, Clarisse, Jonathan Macni, Moustapha Drame, *et al.* *Overall survival of colorectal cancer by stage at diagnosis: Data from the Martinique Cancer Registry. Medicine.* 2019; 98:35(e16941). DOI: <http://dx.doi.org/10.1097/MD.00000000000016941>.
- Junttila, M. R. *et al.* (2015) '*Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer*', *Science Translational Medicine*, 7(314), pp. 1–12. doi: 10.1126/scitranslmed.aac7433.
- Kaur, Kuljit, Adamski, and Jamie J. *Fecal Occult Blood Test (Hemoccult)*. *NCBI*. 2020.
- Kim, Young Joo, Dong Hyun Kang, Geum Jong Song, *et al.* *Clinical relevance of Lgr5 expression in colorectal cancer patients. Korean Journal of Clinical Oncology.* 2018; 14:76-82. DOI : <https://doi.org/10.14216/kjco.18014>
- Komite Penanggulangan Kanker Nasional. *Panduan Penatalaksanaan Kanker Kolorektal. Kementrian Kesehatan RI.* 2017.
- Koo, Si Lin *et al.* *Curative Treatment After Surgery In Colorectal Cancer. Expert Rev Anticancer Ther.* 2013; 13(4):439-450.
- Kuiper, Ernst J, *et al.* *Colorectal Cancer. PMC.* 2016.

- Lee, Chao-Hsien, Shu-Chen Cheng, Hong-Yi Tung, *et al.* *The Risk Factors Affecting Survival in Colorectal Cancer in Taiwan. Iran J Public Health.* 2018; 47(4): pp.519-530.
- Lieu CH, Renfro LA, de Gramont A, *et al.* *Association of age with survival in patients with metastatic colorectal cancer: analysis from the arcad clinical trials program. J Clin Oncol.* 2014; 32, 2975-2.
- Maajani, Khadije, Mahmoud Khodadost, Arash Fattahi, *et al.* *Survival Rate of Colorectal Cancer in Iran: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev.* 20 (1), 13-21. DOI:10.31557/APJCP.2019.20.1.13.
- Manuaba TW. 2010. Panduan Penatalaksanaan Kanker Kolon dan Rektum. Panduan Penatalaksanaan Kanker Solid Peraboi. Sagung Seto. Hal 221-246.
- Mujoomdar M, *et al.* *Fecal Immunochemical Tests for Colorectal Cancer Screening: A Systematic Review of Accuracy and Compliance. CADTH.* 2010.
- Munakata, S., Murai, Y., Koiuzumi, A., Kato, H., Yamamoto, R., Ueda, S., Sato, K. *Long-term outcomes of colorectal cancer patients with and without malignant large-bowel obstruction. Colorectal Cancer.* 2018; 7(2), CRC04. DOI: 10.2217/crc-2018-0001
- Nam MJ, Han KS, Kim BC, *et al.* *Long term outcomes of locally or radically resected T1 colorectal cancer. Colorectal Dis.* 2016; 18:852–860.

Parsaee R, Fekri N, Shahid SS, et al. *Prognostic factors in the survival rate of colorectal cancer patients. J North Khorasan Univ Med Sci.* 2015;7:45–53.

Ramdzan AR, et al. *Diagnostic Accuracy of FOBT and Colorectal Cancer Genetic Testing: A Systematic Review & Meta-Analysis. Annals of Global Health,* 2019.

Robertson, Douglas J. et al. *Recommendations On Fecal Immunochemical Testing To Screen For Colorectal Neoplasia: A Consensus Statement By The US Multi-Society Task Force On Colorectal Cancer. Gastrointestinal Endoscopy.* 2017; 85(1).

Romero, Juan José Granados, et al., *Colorectal cancer: a review. Int J Res Med Sci.* 2017.

Rose J, Augestad KM, and Cooper GS. *Colorectal Cancer Surveillance: What's New and What's Next? World J Gastroenterol.* 2014, 20(8). Pp : 1887-1897.

Rosiq, Saed et al. *Colonic Stem Cells Expression Of Lgr5 And CD133 Proteins As Predictive Markers In Colorectal Cancer Among Egyptian Patients. Open Access Macedonian Journal Of Medical Sciences.* 2018; 6(6): pp. 968-974.

Salehizadeh, Shirin, et al. *The Expression Analysis of Intestinal Cancer Stem Cell Marker Lgr5 in Colorectal Cancer Patients and the*

- Correlation with Histopathological Markers. Journal of Gastrointestinal Cancer.* 2019.
- Sato, K., Uehara, T., Iwaya, M., Nakajima, T., Miyagawa, Y., Suga, T Tanaka, E. *Correlation of clinicopathological features and LGR5 expression in colon adenocarcinoma. Annals of Diagnostic Pathology.* 2019; 40, 161–165. DOI:10.1016/j.anndiagpath.2019.05.002
- Sayuti, Muhammad. Nouva. *Kanker Kolorektal. Jurnal Averrous.* 2019.
- Scheer, Adena, and Rebecca Auer. Surveillance After Curative Resection Of Colorectal Cancer. *Clinics In Colon And Rectal Surgery.* 2009; 22(04): pp. 242-250. Georg Thieme Verlag KG, DOI:10.1055/s-0029-1242464. Accessed 25 May 2020.
- Siegel, Rebecca L. et al., *Colorectal Cancer Statistics, 2020. Ca Cancer J Clin.* 2020.
- Simon, E. et al. (2012) 'The spatial distribution of LGR5+ cells correlates with gastric cancer progression', *PLoS ONE*, 7(4). doi: 10.1371/journal.pone.0035486.
- Sinclair P, Singh A, Riaz AA, and Amin A. *An Unsolved Conundrum: The Ideal Follow-Up Strategy After Curative Surgery for Colorectal Cancer. Gastrointest Endosc.* 2012, 75. Pp :1072–1079.
- Snyder, Rebecca A et al. *Detection And Treatment Of Colorectal Cancer (CRC) Recurrence During Routine Surveillance: A Nationwide Cohort Study. Journal Of Clinical Oncology.* 2016; 34(15): pp. e18137-

e18137. *American Society Of Clinical Oncology (ASCO)*,
DOI:10.1200/jco.2016.34.15_suppl.e18137. Accessed 23 May 2020.

Stanisavljević, Luka & Myklebust, Mette & Leh, Sabine & Dahl, Olav. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer. Acta Oncologica. 2016. 55. 1-9. 10.1080/0284186X.2016.1201215.

Sun, Jie *et al. The Role Of Msept9 In Screening, Diagnosis, And Recurrence Monitoring Of Colorectal Cancer. BMC Cancer. 2019; 19(1). Springer Science And Business Media LLC, DOI:10.1186/s12885-019-5663-8. Accessed 25 May 2020.*

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973–2013 varying)

Tahmasbi, Bahram *et al. Determining the Survival Rate of Colorectal Cancer in Iran: A Systematic Review and Meta-Analysis.” Asian Pacific journal of cancer prevention: APJCP. 2018 19,11 3009-3018. 28 Nov. 2018, doi:10.31557/APJCP.2018.19.11.3009*

Tanaka, Takuji. *et al. Biomarkers for Colorectal Cancer. Int. J. Mol. Sci, 2010.*

Teo MCC, Soo KC. *Cancer trends and incidences in Singapore. Japanese J Clin Oncol. 2013; 43, 219-4.*

Vera, R. *et al.* *Recommendations For Follow-Up Of Colorectal Cancer Survivors. Clinical And Translational Oncology.* 2019; 21(10): pp. 1302-1311. Springer Science And Business Media LLC, DOI:10.1007/s12094-019-02059-1.

World Cancer Research Fund International/American Institute for Cancer Research. *Continuous Update Project Report: Diet, Nutrition, Physical Activity, and Colorectal Cancer. American Institute for Cancer Research.* 2018.

Wu, Xiao-Song, *et al.*, *Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World Journal of Surgical Oncology.* 2012.


Yang, Ling, Yan Lin, Zhihui Liu, *et al.* *Impact of LGR5 in colorectal cancer on overall and progression-free survival: a systematic review and meta-analysis. Int J Clin Exp Med.* 2016; 9(6):10537-10543.

Young, Patrick. E. *et al.* *Early Detection Of Colorectal Cancer Recurrence In Patients Undergoing Surgery With Curative Intent: Current Status And Challenges. Journal Of Cancer,* 2014; 5(4): pp. 262-271. Ivyspring International Publisher, DOI:10.7150/jca.7988.

Zhang, F. Gao, J. Luo, and J. Yang. *Prognostic factors in survival of colorectal cancer patients with synchronous liver metastasis. Colorectal Disease.* 2010; 12(8): pp. 754–761, 2010.

LAMPIRAN

LAMPIRAN 1. SURAT KEPUTUSAN PEMBIMBING MAKALAH AKHIR


KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
 Jl. Perintis Kemerdekaan Kampus Tamalanrea Km. 10 Makassar 90245 Telp. (0411) 5077912, 586010 (0411) 586200
 Fax. 586010 Email : fkunhas@med.unhas.ac.id

SURAT KEPUTUSAN
DEKAN FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN
No.1370/UN4.6/KEP/2020
TENTANG
PENGANGKATAN PEMBIMBING KARYA AKHIR BAGI MAHASISWA
Sdr. : dr. EDWARD JULIO SUHENDRA NOMOR POKOK : C104216105
PROGRAM PENDIDIKAN DOKTER SPESIALIS ILMU BEDAH
FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN

DEKAN FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN

Membaca : Surat Program Pendidikan Dokter Spesialis **Ilmu Bedah** Fakultas Kedokteran Unhas Nomor : 200/KPS.Bed-Sp.IV/20 tanggal 08 April 2020 perihal SK Pembimbing Karya Akhir bagi Sdr. **dr. Edward Julio Suhendra** dengan Judul Penelitian: "**Korelasi Imunoekspresi LGR5 dan FOBT Sebagai Faktor pada Prediksi Kekambuhan pada Adenokarsinoma Kolorektal**"

Menimbang : a. Bahwa dalam rangka pelaksanaan Bimbingan Karya Akhir bagi Sdr. **dr. Edward Julio Suhendra** Mahasiswa Program Pendidikan Dokter Spesialis **Ilmu Bedah** Fakultas Kedokteran Universitas Hasanuddin, dipandang perlu mengangkat Tim Pembimbing Karya Akhir
 b. Bahwa untuk keperluan huruf (a) di atas, maka dipandang perlu menerbitkan surat Keputusannya.

Mengingat : 1. Keputusan Rektor Unhas No. 977/J04/O/2005
 2. Keputusan Rektor Unhas No. 2283/H4/P/2007
 3. Keputusan Rektor Unhas No. 1784/H4.2/K/2010
 4. Keputusan Rektor Unhas No. 1282/H4.2/K/2011
 5. Keputusan Rektor Unhas No. 8650/UN4.2/KU.10/2012
 6. Keputusan Rektor Unhas No. 8765/UN4.2/KU.10/2013


MEMUTUSKAN

Menetapkan :
 Pertama : Membentuk Tim Pembimbing Karya Akhir bagi Sdr. **dr. Edward Julio Suhendra** Mahasiswa Program Pendidikan Dokter Spesialis **Ilmu Bedah** Fakultas Kedokteran Universitas Hasanuddin dengan susunan sebagai berikut :
 1. Dr. dr. Warsingih, Sp.B-KBD Pembimbing Utama
 2. dr. M. Ihwan Kusuma, SpB-KBD Pembimbing Pendamping
 3. dr. Joko Hendarto, M.Biomed, Ph.D Pembimbing Pendamping

Kedua : Segala biaya yang timbul sehubungan dengan Surat Keputusan ini dibebankan pada Anggaran DPA PTN Badan Hukum Tahun 2020 alokasi Fakultas Kedokteran Universitas Hasanuddin.

Ketiga : Surat Keputusan ini berlaku terhitung mulai tanggal ditetapkannya, dengan ketentuan apabila dikemudian hari ternyata terdapat kesalahan atau kekeliruan didalamnya akan diadakan perbaikan sebagaimana mestinya.


Ditetapkan di : Makassar
 Pada tanggal : 17 April 2020

a.n Dekan
Wakil Dekan Bid. Akademik, Riset dan Inovasi


Dr. dr. Irfan Idris, M.Kes
NIP 19671103 199802 1 001

Tembusan :
 1. Ketua Program Studi **Ilmu Bedah**
 2. Masing-masing yang bersangkutan untuk dilaksanakan
 3. **dr. Edward Julio Suhendra**

LAMPIRAN 2. SURAT KEPUTUSAN PENGUJI MAKALAH AKHIR


KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
 Jl. Perintis Kemerdekaan Kampus Tamalanrea Km. 10 Makassar 90245 Telp. (0411) 5077912, 586010 (0411) 586200
 Fax. 586010 Email : fkunhas@med.unhas.ac.id

SURAT KEPUTUSAN
DEKAN FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN
No.1371/UN4.6/KEP/2020
TENTANG
PENGANGKATAN PENILAI SEMINAR USUL DAN HASIL PENELITIAN
Sdr. : dr. EDWARD JULIO SUHENDRA NOMOR POKOK : C104216105
PROGRAM PENDIDIKAN DOKTER SPESIALIS ILMU BEDAH
FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN
DEKAN FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN

Membaca : Surat Program Pendidikan Dokter Spesialis **Ilmu Bedah** Fakultas Kedokteran Unhas Nomor : 199/KPS.Bed-Sp.1/IV/20 tanggal 08 April 2020 tentang Penilai Seminar Usul dan Hasil Penelitian bagi **dr. Edward Julio Suhendra** dengan Judul Penelitian: **"Korelasi Imunoekspresi LGR5 dan FOBT Sebagai Faktor pada Prediksi Kekambuhan pada Adenokarsinoma Kolorektal"**

Menimbang: a. Bahwa dalam rangka pelaksanaan Seminar Usul dan Hasil Penelitian Sdr. **dr. Edward Julio Suhendra** Mahasiswa Program Pendidikan Dokter Spesialis **Ilmu Bedah** Fakultas Kedokteran Universitas Hasanuddin, dipandang perlu mengangkat Tim Penilai.
 b. Bahwa untuk keperluan huruf (a) di atas, maka dipandang perlu menerbitkan surat keputusannya.

Mengingat : 1. Keputusan Rektor Unhas No. 1067/J04/P/2003
 2. Keputusan Rektor Unhas No. 977/J04/O/2005
 3. Keputusan Rektor Unhas No. 2283/H4/P/2007
 4. Keputusan Rektor Unhas No. 1784/H4.2/K/2010
 5. Keputusan Rektor Unhas No. 1282/H4.2/K/2011
 6. Keputusan Rektor Unhas No. 8650/UN4.2/KU.10/2012
 7. Keputusan Rektor Unhas No. 8765/UN4.2/KU.10/2013

MEMUTUSKAN


Menetapkan :
Pertama : Membentuk Tim Penilai Seminar Usul dan Hasil Penelitian bagi Sdr. **dr. Edward Julio Suhendra** Nomor Pokok : **C104216105** Mahasiswa Program Pendidikan Dokter Spesialis **Ilmu Bedah** Fakultas Kedokteran Universitas Hasanuddin dengan susunan sebagai berikut:

1. Dr. dr. Warsinggih, Sp.B-KBD	Penguji Utama
2. dr. M. Ihwan Kusuma, SpB-KBD	Penguji Pendamping
3. dr. Mappincara, Sp.B-KBD	Penguji Pendamping
4. dr. Joko Hendarto, M.Biomed, Ph.D	Penguji Pendamping
5. Dr. dr. Prihantono, Sp.B(K)Onk, M.Kes	Penguji Pendamping

Kedua : Segala biaya yang timbul sehubungan dengan Surat Keputusan ini dibebankan pada Anggaran DPA PTN Badan Hukum Tahun 2020 alokasi Fakultas Kedokteran Universitas Hasanuddin.


Ketiga : Surat Keputusan ini berlaku terhitung mulai tanggal ditetapkannya, dengan ketentuan apabila dikemudian hari ternyata terdapat kesalahan atau kekeliruan di dalamnya akan diadakan perbaikan sebagaimana mestinya.


Ditetapkan di : Makassar
 Pada tanggal : 17 April 2020

a.n Dekan
Wakil Dekan Bid. Akademik, Riset dan Inovasi

Dr. dr. Irfan Idris, M.Kes
NIP 19671103 199802 1 001

Tembusan :
 1. Ketua Program Studi **Ilmu Bedah**
 2. Masing-masing yang bersangkutan untuk dilaksanakan
 3. **dr. Edward Julio Suhendra**

LAMPIRAN 3. SURAT ETHICAL CLEARANCE


KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Agussalim Bukhari.,M.Med.,PhD.,Sp.GK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 120/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 26 Februari 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20080374	No Sponsor Protokol	
Peneliti Utama	dr. Edward Julio Suhendra	Sponsor	
Judul Peneliti	Hubungan Kadar Imunoekspresi Leucine-Rich Repeat Containing G Protein Coupled Receptor 5 (LGR5) terhadap Overall Survival pada Karsinoma Kolorektal		
No Versi Protokol	2	Tanggal Versi	25 Februari 2021
No Versi PSP	2	Tanggal Versi	25 Februari 2021
Tempat Penelitian	RS Dr. Wahidin Sudirohusodo dan Jejaring, Laboratorium PA FKUH Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

LAMPIRAN 4. HASIL ANALISA STATISTIK

Asosiasi LGR5 (tinggi dan rendah) terhadap: umur, jenis kelamin, lokasi tumor, stadium tumor dan grading histopatologi.

Berdasarkan hasil output spss didapatkan nilai hasil uji chi square sebagai berikut:

1. Jenis kelamin

LGR-5 * Jenis Kelamin Crosstabulation

		Jenis Kelamin			
		Perempuan	Laki-Laki	Total	
LGR-5	Tinggi	Count	2	6	8
		% of Total	6.7%	20.0%	26.7%
	Rendah	Count	7	15	22
		% of Total	23.3%	50.0%	73.3%
Total	Count	9	21	30	
	% of Total	30.0%	70.0%	100.0%	

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	.130 ^a	1	.719	1.000	.547	
Continuity Correction ^b	.000	1	1.000			
Likelihood Ratio	.133	1	.715	1.000	.547	
Fisher's Exact Test				1.000	.547	
Linear-by-Linear Association	.126 ^c	1	.723	1.000	.547	.334
N of Valid Cases	30					

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 2.40.

b. Computed only for a 2x2 table

c. The standardized statistic is -.354.

2. Umur

LGR-5 * Umur Crosstabulation

		Umur		Total	
		<40 Tahun	>40 Tahun		
LGR-5	Tinggi	Count	1	7	8
		% of Total	3.3%	23.3%	26.7%
	Rendah	Count	4	18	22
		% of Total	13.3%	60.0%	73.3%
Total	Count	5	25	30	
	% of Total	16.7%	83.3%	100.0%	

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	.136 ^a	1	.712	1.000	.595	
Continuity Correction ^b	.000	1	1.000			
Likelihood Ratio	.143	1	.705	1.000	.595	
Fisher's Exact Test				1.000	.595	
Linear-by-Linear Association	.132 ^c	1	.717	1.000	.595	.411
N of Valid Cases	30					

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.33.

b. Computed only for a 2x2 table

c. The standardized statistic is -.363

3. Stadium Tumor

LGR-5 * Stadium tumor Crosstabulation

		Stadium tumor				Total
		Stadium II	Stadium III	Stadium IV		
LGR-5	Tinggi	Count	1	4	3	8
		% of Total	3.3%	13.3%	10.0%	26.7%
	Rendah	Count	2	10	10	22
		% of Total	6.7%	33.3%	33.3%	73.3%
Total		Count	3	14	13	30
		% of Total	10.0%	46.7%	43.3%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	.180 ^a	2	.914	1.000		
Likelihood Ratio	.179	2	.914	1.000		
Fisher's Exact Test	.525			1.000		
Linear-by-Linear Association	.173 ^b	1	.677	.760	.452	.220
N of Valid Cases	30					

a. 4 cells (66.7%) have expected count less than 5. The minimum expected count is .80.

b. The standardized statistic is .416.

4. Grading histopatologi

LGR-5 * Grading histopatologi Crosstabulation

		Grading histopatologi			Total
		Well differentiated	Moderately differentiated	Poorly differentiated	
LGR-5 Tinggi	Count	2	4	2	8
	% of Total	6.7%	13.3%	6.7%	26.7%
Rendah	Count	1	15	6	22
	% of Total	3.3%	50.0%	20.0%	73.3%
Total	Count	3	19	8	30
	% of Total	10.0%	63.3%	26.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	2.772 ^a	2	.250	.370		
Likelihood Ratio	2.422	2	.298	.370		
Fisher-Freeman-Halton Exact Test	2.645			.301		
Linear-by-Linear Association	.864 ^b	1	.353	.489	.281	.181
N of Valid Cases	30					

a. 3 cells (50.0%) have expected count less than 5. The minimum expected count is .80.

b. The standardized statistic is .930.

5. Lokasi Tumor

LGR5 * Lokasi tumor Crosstabulation

		Lokasi tumor					Total
		Colon ascenden	Colon transversum	Colon descenden	Colon sigmoid	Rectum	
LGR5 Tinggi	Count	1	1	4	2	0	8
	% of Total	3.3%	3.3%	13.3%	6.7%	0.0%	26.7%
Rendah	Count	6	4	7	3	2	22
	% of Total	20.0%	13.3%	23.3%	10.0%	6.7%	73.3%
Total	Count	7	5	11	5	2	30
	% of Total	23.3%	16.7%	36.7%	16.7%	6.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	2.373 ^a	4	.667	.702		
Likelihood Ratio	2.899	4	.575	.689		
Fisher-Freeman-Halton Exact Test	2.172			.857		
Linear-by-Linear Association	.322 ^b	1	.571	.617	.347	.114
N of Valid Cases	30					

a. 8 cells (80.0%) have expected count less than 5. The minimum expected count is .53.

b. The standardized statistic is -.567.

Asosiasi Overall Survival (OS) terhadap : jenis kelamin, usia, stadium, grading histopatologi, lokasi tumor, ekspresi LGR5 tinggi dan rendah.

Berdasarkan hasil output spss didapatkan nilai hasil uji chi square sebagai berikut:

6. Jenis kelamin

OS * Jenis Kelamin Crosstabulation

		Jenis Kelamin			
		Perempuan	Laki-Laki	Total	
OS	3 Years	Count	7	15	22
		% of Total	23.3%	50.0%	73.3%
	5 Years	Count	2	6	8
		% of Total	6.7%	20.0%	26.7%
Total		Count	9	21	30
		% of Total	30.0%	70.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	.130 ^a	1	.719	1.000	.547	
Continuity Correction ^b	.000	1	1.000			
Likelihood Ratio	.133	1	.715	1.000	.547	
Fisher's Exact Test				1.000	.547	
Linear-by-Linear Association	.126 ^c	1	.723	1.000	.547	.334
N of Valid Cases	30					

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 2.40.

b. Computed only for a 2x2 table

c. The standardized statistic is .354.

7. Umur

OS * Umur Crosstabulation

			Umur		Total
			<40 Tahun	>40 Tahun	
OS	3 Years	Count	4	18	22
		% of Total	13.3%	60.0%	73.3%
	5 Years	Count	1	7	8
		% of Total	3.3%	23.3%	26.7%
Total	Count	5	25	30	
	% of Total	16.7%	83.3%	100.0%	

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	.136 ^a	1	.712	1.000	.595	
Continuity Correction ^b	.000	1	1.000			
Likelihood Ratio	.143	1	.705	1.000	.595	
Fisher's Exact Test				1.000	.595	
Linear-by-Linear Association	.132 ^c	1	.717	1.000	.595	.411
N of Valid Cases	30					

a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.33.

b. Computed only for a 2x2 table

c. The standardized statistic is .363.

8. Stadium Tumor

OS * Stadium tumor Crosstabulation

			Stadium tumor			Total
			Stadium II	Stadium III	Stadium IV	
OS	3 Years	Count	0	9	13	22
		% of Total	0.0%	30.0%	43.3%	73.3%
	5 Years	Count	3	5	0	8
		% of Total	10.0%	16.7%	0.0%	26.7%
Total	Count	3	14	13	30	
	% of Total	10.0%	46.7%	43.3%	100.0%	

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	13.563 ^a	2	.001	<.001		
Likelihood Ratio	16.546	2	<.001	<.001		
Fisher-Freeman- Halton Exact Test	12.648			<.001		
Linear-by-Linear Association	12.531 ^b	1	<.001	<.001	<.001	.000
N of Valid Cases	30					

a. 4 cells (66.7%) have expected count less than 5. The minimum expected count is .80.

b. The standardized statistic is -3.540.

9. Grading histopatologi

OS * Grading histopatologi Crosstabulation

			Grading histopatologi			Total
			Well differentiated	Moderately differentiated	Poorly differentiated	
OS	3 Years	Count	1	14	7	22
		% of Total	3.3%	46.7%	23.3%	73.3%
	5 Years	Count	2	5	1	8
		% of Total	6.7%	16.7%	3.3%	26.7%
Total	Count	3	19	8	30	
	% of Total	10.0%	63.3%	26.7%	100.0%	

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	3.277 ^a	2	.194	.245		
Likelihood Ratio	3.047	2	.218	.314		
Fisher's Exact Test	2.953			.245		
Linear-by-Linear Association	2.647 ^b	1	.104	.161	.099	.078
N of Valid Cases	30					

a. 3 cells (50.0%) have expected count less than 5. The minimum expected count is .80.

b. The standardized statistic is -1.627.

10. Lokasi Tumor

OS * Lokasi tumor Crosstabulation

		Lokasi tumor					Total
		Colon ascenden	Colon transversum	Colon descenden	Colon sigmoid	Rectum	
OS 3 Years	Count	7	4	6	3	2	22
	% of Total	23.3%	13.3%	20.0%	10.0%	6.7%	73.3%
5 Years	Count	0	1	5	2	0	8
	% of Total	0.0%	3.3%	16.7%	6.7%	0.0%	26.7%
Total	Count	7	5	11	5	2	30
	% of Total	23.3%	16.7%	36.7%	16.7%	6.7%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	5.826 ^a	4	.212	.230		
Likelihood Ratio	7.903	4	.095	.173		
Fisher-Freeman-Halton Exact Test	5.391			.249		
Linear-by-Linear Association	1.558 ^b	1	.212	.240	.143	.064
N of Valid Cases	30					

a. 8 cells (80.0%) have expected count less than 5. The minimum expected count is .53.

b. The standardized statistic is 1.248.

11. LGR-5

OS * LGR-5 Crosstabulation

		LGR-5		Total	
		Tinggi	Rendah		
OS	3 Years	Count	5	17	22
		% of Total	16.7%	56.7%	73.3%
	5 Years	Count	3	5	8
		% of Total	10.0%	16.7%	26.7%
Total		Count	8	22	30
		% of Total	26.7%	73.3%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)	Point Probability
Pearson Chi-Square	.655 ^a	1	.418	.643	.355	
Continuity Correction ^b	.117	1	.732			
Likelihood Ratio	.628	1	.428	.643	.355	
Fisher's Exact Test				.643	.355	
Linear-by-Linear Association	.633 ^c	1	.426	.643	.355	.252
N of Valid Cases	30					

a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 2.13.

b. Computed only for a 2x2 table

c. The standardized statistic is -.796.

